APA (7th ed.) Citation

S, W., C, D., Y, S., H, Z., W, Z., J, Z., . . . D, C. (2026). Osteoporosis therapies and coronary risk: Insights from vascular calcification biology and sclerostin signaling. Frontiers in endocrinology, 17, 1839111. https://doi.org/10.3389/fendo.2026.1839111

Chicago Style (17th ed.) Citation

S, Weng, Ding C, Shi Y, Zhang H, Zhao W, Zhu J, Peng F, and Chai D. "Osteoporosis Therapies and Coronary Risk: Insights from Vascular Calcification Biology and Sclerostin Signaling." Frontiers in Endocrinology 17 (2026): 1839111. https://doi.org/10.3389/fendo.2026.1839111.

MLA (9th ed.) Citation

S, Weng, et al. "Osteoporosis Therapies and Coronary Risk: Insights from Vascular Calcification Biology and Sclerostin Signaling." Frontiers in Endocrinology, vol. 17, 2026, p. 1839111, https://doi.org/10.3389/fendo.2026.1839111.